New Drug Harnesses Potential Positive Effects of Natural Virus on Cancer Patients

A naturally-occurring, harmless human virus may have the power to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published by Clinical Cancer Research.

A new drug called RT3D (trade name Reolysin) — developed by Oncolytics Biotech Inc., with preclinical and clinical studies conducted at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital — is based on the virus (reovirus type 3 Dearing) that is found in almost every adult’s respiratory and gastrointestinal tracts without causing any symptoms. For more information, click here to read the full release.